Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children

Journal Article

2010

Permanent link to this Item
http://hdl.handle.net/11427/15647
 http://dx.doi.org/10.1186/1758-2652-13-S4-O24
Files
Zhang_Population_pharmacokinetics_2010.pdf (181.85 KB)
Authors
Zhang, C
Denti, P
Simonsson, USH
Maartens, Gary
Karlsson, MO
McIlleron, H
Journal Title

Journal of the International AIDS Society

Link to Journal
http://www.jiasociety.org/index.php/jias
Journal ISSN
Volume Title
Publisher

Springer

Publisher

University of Cape Town

Department
Division of Clinical Pharmacology
Faculty
Faculty of Health Sciences
License

http://creativecommons.org/licenses/by/2.0

Series
Abstract
Children with HIV associated tuberculosis often require co-formulated lopinavir/ritonavir (LPV/RTV)-based antiretroviral treatment with rifampicin-based antitubercular treatment (ATT). Rifampicin (RIF), a potent inducer of drug-metabolizing systems, profoundly reduces the bioavailability of LPV. The aims of this study were to develop an integrated population pharmacokinetic (PK) model describing LPV and RTV PK in children with and without concomitant ATT using two different dosing approaches and to estimate doses of LPV/RTV achieving target exposures during ATT in young children.
Description
Keywords
Population pharmacokinetics
lopinavir
ritonavir

Reference:

Zhang, C., Denti, P., Simonsson, U. S. H., Maartens, G., Karlsson, M. O., & McIlleron, H. (2010). Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children. Journal of the International AIDS Society, 13(Suppl 4), O24.

Collections
Journal Articles